SP100-Derived RMSP1 Peptide for Low-Cytotoxicity Atopic Dermatitis Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis, such as steroids and antihistamines, have significant side effects and there is a need for a safe and effective alternative.
Innovation Solution
A peptide derived from human SP100 protein, specifically RMSP1, which reduces cellular inflammatory responses and promotes wound healing, is used to treat atopic dermatitis, and can be modified by various chemical processes and conjugated with biocompatible polymers or fatty acids.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If steroids and antihistamines are used to treat atopic dermatitis, then the treatment efficacy is improved, but serious side effects occur
Solution Approach 1:
The patent extracts the active functional segment from the full-length SP100 protein, isolating a specific peptide sequence (RMSP1: LEKHSGKRRKKRRHR, 15 amino acids) that retains the anti-inflammatory and wound-healing activities while eliminating the harmful effects of the complete protein. This extraction principle allows the therapeutic function to be separated from potential toxicities present in the full protein.
Solution Approach 2:
The patent modifies the protein by changing its length parameter from the full-length SP100 protein (549 amino acids) to a truncated peptide (15 amino acids). This parameter change reduces the molecular size and potentially harmful interactions while preserving the core functional domains responsible for anti-inflammatory activity and wound healing, thereby improving the safety profile.
2Reliability
If full-length SP100 protein is used, then the anti-inflammatory activity is strong, but the cytotoxicity increases
Solution Approach 1:
The patent extracts and isolates a specific functional peptide segment from the full-length SP100 protein, removing the portions that contribute to cytotoxicity while retaining the anti-inflammatory activity. The extracted RMSP1 peptide (15 amino acids) maintains the core functional motifs necessary for anti-inflammatory effects but eliminates the harmful cytotoxic regions present in the full protein.
Solution Approach 2:
The patent segments the full-length SP100 protein into functional domains, identifying and isolating the specific peptide region (amino acids 526-540) that contains the anti-inflammatory activity. This segmentation allows the therapeutic function to be separated from the cytotoxic portions of the protein, creating a safer peptide therapeutic.
Data Source
AI summary
The present invention relates to a peptide exhibiting an anti-inflammatory function, a fusion compound containing the same, and pharmaceuticals, cosmetics, foods, medical devices, etc. containing the same, wherein the present inventors have found that the peptide of SEQ ID NO: 40 and a variant thereof exhibit low cytotoxicity, significantly reduce cellular inflammatory responses induced by lipopolysaccharide, and also exhibit wound healing efficacy.